Also listed under Uterine Cervical Diseases
ClinicalTrials.gov term: Uterine Cervical Neoplasms
Cervical Cancer clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05
What changed in the last 30 days
41 trials changed in the last 30 days: 0 stopped, 20 with notable changes, 21 with minor changes only.
- Notable: RAINFOL-01 · Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Primary completion pushed from Jul 2027 to Dec 2028
- Notable: CAMPERR · CfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease Primary completion pushed from Mar 2026 to Dec 31, 2026
- Notable: Community, Home-based Education, Screening Services Strategy to Increase Cervical Cancer Control Access for HIV-Positive Women in Nigeria Primary and study completion pushed from Jun 2026 to Aug 2028
- Notable: CERBERO · Gut Microbiome · Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers Start date pushed from Oct 1, 2026 to Nov 11, 2026
- Minor: AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) Primary completion pushed from Aug 31, 2026 to Dec 31, 2026
- Minor: DEFEND · Distance-Based Exercise to Preserve Function and Prevent Disability Trial sites expanded: 23 → 30 locations
- Minor: Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor · Locally Advanced or Metastatic Solid Tumors Trial sites reduced: 36 → 32 locations
- Minor: DOVE · Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) Enrollment closed, study ongoing
- Minor: ARC-25 · AB598 Monotherapy and Combination Therapy · Advanced Cancers Trial sites expanded: 14 → 19 locations
- Notable: ABILITY-1 · Beta-only IL-2 ImmunoTherapY Study Primary completion pushed from Nov 30, 2026 to Oct 20, 2028
- Notable: Ameliorated Pap Tests and Cervical Cancer Screening Participation Enrollment increased: 248 → 850 participants
- Notable: C2001P-CS3 · Different HPV Screening and Care Strategies · HIV Primary and study completion pushed from Jun 1, 2027 to May 31, 2028
- Notable: Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia Primary completion pushed from Dec 30, 2025 to Dec 30, 2027
- Minor: OvAR-Y · Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women Trial completed
- Minor: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) Trial sites expanded: 180 → 191 locations
- Notable: TER-2013 · Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations Primary endpoint(s) modified
- Notable: MGC026 · Advanced Solid Tumors Enrollment increased: 250 → 394 participants
- Minor: ALE.P02 as a Monotherapy or in Combination With Pembrolizumab · Selected CLDN1+ Solid Tumors Enrollment increased: 170 → 235 participants
- Minor: Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer Trial sites expanded: 343 → 346 locations
- Minor: Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade · HIV in South Africa: Part 2 Trial completed
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-02 | NCT07909031 CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. new | Phase 1/2 |
| 2026-10-15 | NCT07876154 Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant… | Xijing Hospital new | Phase 2 |
| 2026-10-08 | NCT07865650 PEG-rhG-CSF Primary Prophylaxis vs Therapeutic Short-Acting rhG-CSF for Neutropenia… | The Second Hospital of Anhui Medical University new | |
| 2026-10-07 | NCT07863596 Cervical Cancer Awareness Education to Aid Confidence and Screening upTake (ACT): A Pilot… | Teesside University new | |
| 2026-10-06 | NCT07860203 Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing… | Catherin Zhang new | |
| 2026-10-05 | NCT07856862 Culturally Adapted Materials to Increase Cervical Cancer Screening Among Polish Women in… | The Primary Health Care in the Capital Area new | |
| 2026-09-11 | NCT07815873 Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in… | European Institute of Oncology new | |
| 2026-09-08 | NCT07807202 Improving HPV Vaccination Coverage Among Adolescent Girls in Mali and Côte d'Ivoire… | Muso Health new | |
| 2026-08-31 | NCT07795385 Embodied Conversational Agents for CervicalCancer Screening Abnormalities | Tufts Medical Center new | |
| 2026-08-25 | NCT07784283 Integrating HPV Education Into School Health Programs in Cambodia and Kenya | Clinton Health Access Initiative Inc. new |
Active trials by phase
| Early Phase 1 | 4 | |
| Phase 1 | 67 | |
| Phase 1/2 | 61 | |
| Phase 2 | 152 | |
| Phase 2/3 | 8 | |
| Phase 3 | 44 | |
| Phase 4 | 14 |
Not charted: 417 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
M.D. Anderson Cancer Center (21) · National Cancer Institute (NCI) (15) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (14) · Peking Union Medical College Hospital (13) · Mayo Clinic (11) · Chongqing University Cancer Hospital (10) · Obstetrics & Gynecology Hospital of Fudan University (9) · Tata Memorial Hospital (9) · Fujian Cancer Hospital (8) · UNC Lineberger Comprehensive Cancer Center (8)
Get alerts when Cervical Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.